Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Pine bark extract reduces jetlag

A new study published in the journal of Minerva Cardioangiologica reveals Pycnogenol, pine bark extract from the French maritime pine tree, reduces jetlag in passengers by nearly 50 percent.

6 Nov 2008

Scientists map molecular regulation of fat-cell genetics

A research team led by Mitchell Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania School of Medicine, has used state-of-the-art genetic technology to map thousands of positions where a molecular "master regulator" of fat-cell biology is nestled in DNA to control genes in these cells.

5 Nov 2008

Scientists map molecular "master regulator" of fat-cell biology

5 Nov 2008

Anti-VEGF drugs for retinal diseases could have serious side effects

Scientists at Schepens Eye Research Institute have found that reducing the levels of vascular endothelial growth factor (VEGF), which is best known as a stimulator of new blood vessel growth, in adult mice causes the death of photoreceptors and Muller glia -- cells of the retina that are essential to visual function.

3 Nov 2008

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.

31 Oct 2008

Bisphosphonates for osteoporosis increase risk for heart problems

People who take bisphosphonates for osteoporosis may be at risk for serious atrial fibrillation (AF), or irregular heartbeats, according to a new study.

27 Oct 2008

Data Safety Monitoring Board supports continuation of trial of Iluvien for diabetic macular edema

pSivida Corp. has announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change.

25 Sep 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Maternal deaths following cesarean delivery can be reduced

Maternal death rates have remained constant in the United States for many decades. Are there any improvements in health care that could reduce these rates further?

4 Aug 2008

Laser therapy more effective than corticosteroids in long term treatment of diabetic macular edema

A promising new drug therapy used to treat abnormal swelling in the eye - a condition called diabetic macular edema - proved less effective than traditional laser treatments in a study funded by the National Eye Institute (NEI), part of the National Institutes of Health (NIH).

29 Jul 2008

New clues into how preeclampsia may surface in some pregnancies

The COMT gene - known already for its role in schizophrenia - has been found to play a role in preeclampsia, according to a report in the advance on-line issue of Nature.

11 May 2008

FDA approves Amitiza for irritable bowel syndrome with constipation

The U.S. Food and Drug Administration today approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over.

29 Apr 2008

Ranibizumab therapy for diabetic eye disease shows promise

A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

29 Apr 2008

Tredaptive and Janumet recommended for approval in European Union

Food and Drug Administration (FDA) is currently reviewing the combination of extended release (ER) niacin and laropiprant under the trademark Cordaptive (ER niacin/laropiprant). The CHMP recommendation does not apply to regulatory decisions by the FDA and no inferences should be made about pending FDA regulatory actions based on the recommendation of the CHMP.

24 Apr 2008

New mucosal vaccine against anthrax effective in early tests

Early studies show that a new mucosal vaccine against anthrax has the potential to provide military personnel with more effective and efficient protection against a "popular" bioweapon, according to a study published in the journal Clinical and Vaccine Immunology (CVI).

13 Apr 2008

The mysterious link between summer birthdates and myopia

Do corneas from older donors meet quality standards for transplant surgery? These are among the topics explored in the April 2008 issue of Ophthalmology, the journal of the American Academy of Ophthalmology.

2 Apr 2008

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics

Results of a randomised trial published in PLoS Medicine show no benefit in cognitive or neuropsychiatric outcomes from continuing neuroleptic drugs in patients with Alzheimer's disease.

1 Apr 2008

New blood pressure drug telmisartan has fewer side effects

A major Canadian-led global study has found that a new blood pressure medication is effective in reducing cardiovascular death, with fewer side effects than the current standard of care.

1 Apr 2008

Naglazyme approved in Japan

BioMarin Pharmaceutical Inc. has announced that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing Application for Naglazyme(R) (galsulfase) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with Mucopolysaccharidosis VI ( MPS VI).

1 Apr 2008

Watery pools in bone marrow key to psoriatic arthritic damage

Researchers have learned more about how a leading drug prevents certain types of arthritis from eating away at bone, according to a study published in the March edition of the Annals of the Rheumatic Diseases.

4 Mar 2008